Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease
16 November 2022
Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.
Mathematician boosts data science research at the Kennedy Institute
19 October 2022
Welcome to Yang Luo who has joined the Kennedy Institute as the Principal Investigator of the Luo Group. Her lab is leading the investigation into how genetic variations contribute to diseases of the immune system.
NIHR funding for musculoskeletal and inflammatory disease research
17 October 2022
Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.
Leducq Foundation grant boosts cardiovascular research
11 October 2022
The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.
MRC funding awarded to Kennedy researchers
8 September 2022
Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.
Kennedy programmes support early career researchers
22 July 2022
Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.
Welcome to the new Kennedy Trust CEO
12 July 2022
The Kennedy Trust has announced Dr Stephen Simpson as its new Chief Executive Officer from 1 July 2022.
Kennedy researchers awarded funding to improve the understanding of inflammatory bowel diseases
5 July 2022
A new £1.5M grant from the Medical Research Council (MRC) to the Powrie Group at the Kennedy Institute will help define different pathotypes of inflammatory bowel diseases that could lead to better and more focused treatments for patients.
Yoshi Itoh wins the International Dupuytren Award 2022
30 June 2022
Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.
NDORMS researchers awarded Associate Professor title
22 June 2022
The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.
Professor Fiona Powrie recognised in Queen’s Birthday Honours
6 June 2022
Professor Fiona Powrie was honoured in the 2022 Queen’s Birthday Honours List, published as Her Majesty celebrates her Platinum Jubilee.
The Kennedy Retreat
26 May 2022
The whole of the Kennedy Institute decamped to St Catherine’s college in Oxford on 23/24 May to share and celebrate the Institute’s science, and to strengthen ties across individual research groups. It was great to have everyone back together face to face and the event was buzzing with excitement.
Breakthrough in treatment for Dupuytren’s disease
30 April 2022
Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.
Microbiome research at the Kennedy receives £2.8 million funding
19 April 2022
The Kennedy Institute has been announced as one of 7 new research clusters by the MRC National Mouse Genetics Network
Wellcome Trust Investigator Award for Professor Arnon
12 April 2022
Congratulations to Professor Arnon on her successful Wellcome Trust Investigator Award entitled: “Spatiotemporal basis of adaptive immunity in the spleen.”
New research suggests targeting blood vessels could be key to controlling fibrotic disease
1 April 2022
By studying blood vessels at single cell resolution, Professor Jagdeep Nanchahal and colleagues found that in Dupuytren’s disease, a fibrotic disorder of the hand, the vasculature is key to orchestrating the development of human fibrosis.
Defining the role of resident memory B cells in the fight against influenza
31 March 2022
Researchers at the Kennedy Institute of Rheumatology have used 3D and live-imaging to show how resident memory B cells boost antibodies to fight influenza.
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
23 March 2022
The COVID-19 Multi-omic Blood Atlas (COMBAT) has identified blood hallmarks of COVID-19 involving particular immune cell populations and their development, components of innate and adaptive immunity, and connectivity with the inflammatory response.
Oxford researchers awarded funding to study the immune response to malaria
15 March 2022
Professors Matthew Higgins and Michael Dustin from the University of Oxford, Prof Gavin Wright from the University of York, and Professors Shiroh Iwanaga and Hisashi Arase from Osaka University have secured a Wellcome Collaborative Award for their study “How do RIFINs and STEVORs modulate human immunity during malaria?”
New funding awarded to study persistent pain in inflammatory arthritis
7 March 2022
The £3.9M Wellcome Collaborative Award will be used to identify the drivers of pain in people living with rheumatoid arthritis.